We investigated whether patients with peripheral arterial disease (PAD) with various serum levels of high-sensitivity C-reactive protein (hsCRP) differ in the frequency of atherosclerotic risk factors. Among 388 patients, hsCRP levels were (1) low, <1 mg/L, in 41 (10.6%) participants; (2) medium, from 1 to 3 mg/L, in 152 (39.2%) participants, and (3) high, >3 mg/L, in 195 (50.2%) individuals. According to multivariate logistic regression analysis, in comparison with patients with hsCRP level ≤3.0 mg/L, those with higher hsCRP levels had more frequently a severe form of PAD (gangrene, P ranged from .045 to <.001; ankle–brachial index ≤.40, P = .059) and had more frequently some of atherosclerotic risk factors (metabolic syndrome, P = .007; hypertension, P = .013; abdominal obesity, P = .007; high levels of uric acid, P = .022; high level of fibrinogen, P < .001; and depression, P = .015).
RidkerPMCushmanMStampferMJTracyRPHennekensCH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973–979.
2.
CaoJJThachCManolioTA. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108(2):166–170.
3.
RidkerPMCushmanMStampferMJTracyRPHennekensCH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97(5):425–428.
4.
RossiEBiasucciLMCitterioFPelliccioniSMonacoCGinntettiF. Risk of myocardial infection and angina in patients with severe peripheral arterial disease: predictive role of C-reactive protein. Circulation. 2002;105(7):800–803.
5.
SilvestroAScopacasaFRuoccoA. Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med. 2003;8(4):225–232.
6.
ShankarALiJNietoJF, Klein BE, Klein R. Association between C- reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am Heart J. 2007;154(3):495–501.
7.
TillettWSFrancesTJr. Serological reactions in pneumonia with a non-protein fraction of pneumococcus. J Exp Med. 1930;52(4):561–571.
8.
BallouSPKushnerI. C-reactive protein and the acute phase response. Adv Int Med. 1992;37(3):313–336.
9.
RidkerPM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention [review]. Circulation. 2003;107(3):363–369.
10.
VainasTStassenFRde GraafR. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg. 2005;42(2):243–251.
11.
RidkerPMHennekensCHBuringJE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–843.
12.
GreenlandPAbramsJAurigemmaGP. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerosis burden: Writing Group III. Circulation. 2000;101(1):e16–e22.
13.
CriquiMHFonekAKlauberMR, Barrett-Connor E, Gabriel S. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation. 1985;71(3):515–522.
14.
AronowWS. Management of peripheral arterial disease of the lower extremities in elderly patients. J Gerontol. 2004;59A(2):172–177.
15.
World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Geneva, Switzerland: WHO; 1998.
16.
DurninJVGAWomersleyJ. Body fat assessed from total body density and its estimation from skin fold thickness; measurements on 481 men and women aged from 16 to 72 years. Br J Nutr. 1974;32(1):77–97.
17.
Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252.
18.
PearsonTAMensahGAAlexanderRW, et al, for the Centers for Disease Control and Prevention and the American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511.
19.
GrundySMCleemanJIDanielsSR. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–2752.
20.
BeckATWardCHMendelsonMMockJErbaughJ. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(4):561–571.
21.
BeckATSteerRAGarbinMG. Psychometric properties of the beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8(1):77–100.
22.
BaeckeJABuremaHJFritjersJER. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982;36(5):932–942.
23.
AbdellaouiAAl-KhaffafH. C-reactive protein (CRP) as a marker in peripheral vascular disease. Eur J Vasc Endovasc Surg. 2007;34(1):18–22.
24.
VuJDVuJBPioJR. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, Diabetes Mellitus, and pre-existing cardiovascular disease. Am J Cardiol. 2005;96(5):655–658.
25.
RidkerPMStampferMJRifaiN. Novel risk factors for systematic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J Am Med Assoc. 2001;285(19):2481–2485.
26.
RidkerPMRifaiNRoseLBuringJECookNR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–1565.
27.
TzoulakiIMurrayGDLeeAJRumleyALoweGDOFowkesFGR. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh artery study. Circulation. 2005;112(7):976–983.
28.
McDermottMMGreenDGreenlandP. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol. 2003;92(2):194–199.
29.
McDermottMMGuralnikJMGreenlandP. Inflammatory and thrombotic blood markers and walking-related disability in men and women with and without peripheral arterial disease. J Am Geriatr Soc. 2004;52(11):1888–1894.
30.
BeckmanJAPreisORidkerPMGerhard-HermanM. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol. 2005;96(10):1374–1378.
31.
VainasTLubbersTStassenFR. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurismal tissue. Circulation. 2003;107(8):1103–1105.
32.
HozawaAOhmoriKKyriyamaS. C-reactive protein and peripheral artery disease among Japanese elderly: the Tsurugaya Project. Hypertens Res. 2004;27(12):955–961.
33.
DaskalopoulouSSPathmarajahMKakkosSK. Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J. 2008;72(3):441–448.
34.
MeruAVMittraSThyagarajanBChughA. Intermittent claudication: an overview. Atherosclerosis. 2006;187(2):221–237.
35.
HankeyGJNormanPEEikelboomJW. Medical treatment of peripheral arterial disease. JAMA. 2006;295(5):547–553.
36.
MarsoSPHiattWR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47(5):921–929.
37.
NakouESLiberopoulosENMilionisHJElisafMS. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol. 2008;6(4):258–270.
38.
TennentGAHutchinsonWLKahanMC. Transgenic human CRP is not pro-atherogenic, in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2005;102(23):8309–8314.
39.
PitsavosCPanagiotakosDBTzimaN. Diet, exercise and C-reactive protein levels in people with abdominal obesity: the ATTICA epidemiological study. Angiology. 2007;58(2):225–233.
40.
ParaskevasKIBessiasNPapasTTAndrikopoulosVMikhailidisDP. Is high sensitivity C-reactive protein associated with peripheral atherosclerosis? Angiology. 2009;60(1):8–11.
41.
WattanakitKFolsomARSelvinE. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2005;180(2):389–397.
42.
JohnsonBDKipKEMarroquinOC. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109(6):726–732.
43.
McDermottMMGuralnikJMCorsiA. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J. 2005;150(2):276–281.
44.
OwensCDRidkerPMBelkinM. Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg. 2007;45(1):2–9.
45.
DoweikLMacaTSchillingerMBudinskyASabetiSMinarE. Fibrinogen predicts mortality in high risk patients with peripheral artery disease. Eur J Vasc Endovasc Surg. 2003;26(4):381–386.
46.
KoenigW.Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003;89(4):601–609.
47.
GagliardiACMinameMHSantosRD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202(1):11–17.
48.
KanellisJKangDH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25(1):39–42.
49.
SantosACLopesCGuimarãesJTBarrosH. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes (Lond). 2005;29(12):1452–1456.
50.
FestaAD'AgostinoRHowardJrMykkaneneLTracyRHaffnerS. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42–47.
51.
LiuZMHoSC. The association of serum C-reactive protein, uric acid and magnesium with insulin resistance in Chinese postmenopausal women with prediabetes or early untreated diabetes. Maturitas. 2011;70(2):176–181.
52.
LinSDTsaiDHHsuSR. Association between serum uric acid level and components of the metabolic syndrome. J Chin Med Assoc. 2006;69(11):512–516.
53.
LemieuxIPascotAPrud'hommeD. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001;21(6):961–967.
54.
MertensIVan GaalLF. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002;3(2):85–101.
55.
SchillingerMExnerMMlekuschW. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J. 2004;25(9):742–748.
56.
AthyrosVGMikhailidisDPLiberopoulosEN. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007;22(1):118–127.
